Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 12;47(4):947–957. doi: 10.1007/s00259-019-04530-1

Fig. 4.

Fig. 4

When selecting lesions with comparable baseline SUVmax ranging from 15 to 40, SUVmax showed no significant decrease in group B (Δ%= −7.3 ± 24.5%, P=0.214), significant decrease in group C (Δ%= −34.9 ± 12.4%, P=0.001) and group D (Δ%= −17.9 ± 19.7%, P=0.012) as compared to group A with increased SUVmax (Δ%= 8.4 ± 48.8%).